All In Biotech

Free tool

FDA Approval Tracker

Original approvals of brand-name drugs and biologics (NDAs and BLAs) and efficacy supplements, which add a new use, population or dose. Approvals by CBER (most vaccines, blood products and cell and gene therapies) are not in Drugs@FDA and so are missing.

Last checked: Nov 20, 2026Latest source record: Feb 20, 2026Drugs@FDA last updated: Nov 18, 2026Methods & limitations

Reset

Matching approvals

7

2023 to 2026

Breakthrough

0

Accelerated

0

Priority review

1

Orphan

0

By year

NDAs and BLAs matching the filters.

  • NDA
  • BLA
View as table
YearNDABLA
202340
202420
202500
202610

7 approvals

Newest first. Hover a badge for what it means.

  • Bysanti (Milsaperidone) · Vanda Pharms INCFeb 20, 2026
    Original approval · NDA 220358NovelApproval letter

    To treat schizophrenia and to treat manic or mixed episodes associated with bipolar I disorder

  • Cobenfy (Trospium Chloride, Xanomeline Tartrate) · Bristol-MyersSep 26, 2024
    Original approval · NDA 216158NovelApproval letter

    To treat schizophrenia

  • Opipza (Aripiprazole) · Xiamen Lp Pharm COJul 22, 2024
    Original approval · NDA 216655Approval letter
  • Exxua (Gepirone Hydrochloride) · Fabre KramerSep 22, 2023
    Original approval · NDA 021164NovelApproval letter

    To treat major depressive disorder

  • Zurzuvae (Zuranolone) · BiogenAug 4, 2023
    Original approval · NDA 217369NovelPriority reviewApproval letter

    To treat postpartum depression

  • Uzedy (Risperidone) · TevaApr 28, 2023
    Original approval · NDA 213586Approval letter
  • Abilify Asimtufii (Aripiprazole) · OtsukaApr 27, 2023
    Original approval · NDA 217006Approval letter

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.